In addition, bexarotene reduces CCL22 production by M2 macrophages, which decreases serum CCL22 levels, leading to inhibition of the migration of CTCL cells in the lesional skin of CTCL to suppress CTCL disease activity.2, 4. Here, CCL22 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.